Inozyme Pharma clinical trial pipeline

4 trials changed in the last 30 days: 4 stopped, 0 with notable changes, 0 with minor changes only.

1. Stopped

   ENERGY · ENERGY Study: Evaluation of Safety and Tolerability of…ENERGY · ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 · ENPP1 Deficiency or ABCC6 Deficiency

   Trial terminated

   Sponsor's reason: The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.

   Also in this update: Final enrollment: 9 participants (planned 16)

   Inozyme Pharma·Phase 1· NCT05734196· Registry history of NCT05734196 on ClinicalTrials.gov (opens the registry)

   Updated Oct 15, 2026

2. Stopped

   ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701…ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 · ENPP1 Deficiency

   Trial terminated

   Sponsor's reason: The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.

   Also in this update: Primary endpoint(s) modified; Trial sites reduced: 15 → 11 locations

   Inozyme Pharma·Phase 3· NCT06046820· Registry history of NCT06046820 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

3. Stopped

   ENERGY 2 · INZ-701 · ENPP1 Deficiency

   Trial terminated

   Sponsor's reason: Following review of the totality of program data, the sponsor decided to discontinue development of INZ701. The decision was not related to safety.

   Also in this update: Final enrollment: 2 participants (planned 12); Primary completion date changed from estimate of Oct 14, 2026 to Aug 31, 2026

   Inozyme Pharma·Phase 3· NCT07473973· Registry history of NCT07473973 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

4. Stopped

   PROPEL - A Prospective Observational Patient Registry to Evaluate…PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

   Trial terminated

   Sponsor's reason: The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.

   Inozyme Pharma·Not specified· NCT06302439· Registry history of NCT06302439 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.